ライフサイエンスコーパス: polyoma

1 Comparisons of polyoma and SV40 small T antigens implicate Abeta in the

2 kinase cascade and indicate that the similar polyoma and SV40 small T-antigens influence PP2A to acti

3 anglioside synthesis is poorly infectible by polyoma and SV40, but addition of the appropriate gangli

4 have also been identified in members of the polyoma- and adenovirus families.

5 Hsp70 chaperones play a role in polyoma- and papillomavirus assembly, as evidenced by th

6 ic Hsp70 chaperones efficiently disassembled polyoma- and papillomavirus-like particles and virions i

7 Lipid binding sites for polyoma are shown to be present in rough ER membranes, s

8 ars to be a safe and effective treatment for Polyoma BK nephropathy.

9 Polyoma BK virus produces an aggressively destructive ne

10 24.2%), flu-like syndrome (11.6% vs 14.1%), polyoma (BK) viremia (8.2% vs 11.1%), and herpes simplex

11 er hematopoietic cell transplantation (HCT), polyoma-BK virus is associated with hemorrhagic cystitis

12 uirement for upstream elements including the polyoma enhancer A-binding protein-3 site (-83 to -91) a

13 They also induced the expression of polyoma enhancer activator 3 (PEA3) and increased its DN

14 ed the OPN promoter through two of its PEA3 (polyoma enhancer activator 3) sites.

15 actors of the AML (core binding factor-alpha/polyoma enhancer binding protein 2) class are key transa

16 corticoid-response elements and multiple ets/polyoma enhancer-binding 3 elements, were identified.

17 tors of the acute myelogenous leukemia (AML)/polyoma enhancer-binding protein (PEBP2alpha)/core-bindi

18 nding factoralpha-1/acute myeloid leukemia 3/polyoma enhancer-binding protein 2alphaA/osteoblast-spec

19 erpes simplex thymidine kinase promoter with polyoma enhancers, inserted into two defined chromosomal

20 The combined induction of c-fos, c-jun, and polyoma enhancing activator-3 (pea-3) by H. pylori cause

21 e activity of activator protein-1 (AP-1) and polyoma enhancing activity-3/E26 virus (PEA3/ETS) transc

22 cells as essential effectors in eliminating polyoma-infected and polyoma-transformed cells in vivo.

23 specific CD8+ T cells freshly explanted from polyoma-infected mice, suggesting that a single TCR reco

24 In addition, polyoma-infected resistant mice possess a 10- to 20-fold

25 ted by antiviral CD8(+) T cells during acute polyoma infection and is responsible for down-regulating

26 Urological complications and polyoma infection were the most significant risk factors

27 like particles (VLPs) derived from the human polyoma JC virus.

28 Rb proteins with viral oncoproteins such as polyoma large T (PyLT) antigen and Adenovirus E1A.

29 NK-1 carbohydrate, and a vector encoding the polyoma large T antigen.

30 erences between the classical T=7 capsid and polyoma-like capsids were also identified.

31 he middle T antigen of the DNA tumour virus, polyoma, localization to membranes in a specific manner

32 In the mouse mammary tumor virus-Polyoma Middle T (MMTV-PyMT) model of luminal breast can

33 eloped, we use the mouse mammary tumor virus-Polyoma Middle T (MMTV-PyMT), which mimics RANK and RANK

34 addresses the role of the three isoforms in polyoma middle T (PyMT) and ErbB2/Neu-driven mammary ade

35 hamster ovary cells expressing Mgat3 and the polyoma middle T (PyMT) antigen have reduced cell prolif

36 In mouse mammary tumor virus-polyoma middle T (PyMT) breast cancer mouse model, SRC-1

37 blished cohorts of mouse mammary tumor virus-polyoma middle T (PyMT) PAR1(-/-) and PAR2(-/-) mice, co

38 ct of tumor- or stromal cell-derived CTSB on Polyoma Middle T (PyMT)-induced breast cancer progressio

39 of p110alpha blocks tumor formation in both polyoma middle T antigen (MT) and HER2/Neu transgenic mo

40 (PI3K), while breast cancer driven by either polyoma middle T antigen (MT) or HER2 is p110alpha depen

41 the consensus sequence of the viral hamster polyoma middle T antigen (pYEEI) were characterized.

42 instillation of an RCAS vector carrying the polyoma middle T antigen (PyMT) gene (RCAS-PyMT) induced

43 with FVB mice and then cross-bred with MMTV-polyoma middle T antigen (PyMT) mice to investigate the

44 Using the MMTV-Polyoma Middle T antigen (PyMT) mouse model of human duc

45 f transgenic mammary tumors caused by either Polyoma middle T antigen (PyMT) or activated Neu/ErbB2.

46 ic overexpression of c-myc, c-neu, c-ha-ras, polyoma middle T antigen (PyMT) or simian virus 40 T/t a

47 ith mammary gland-targeted expression of the polyoma middle T antigen (PyMT) transgene develop primar

48 n-A (Fet) in mammary tumorigenesis using the polyoma middle T antigen (PyMT) transgenic mouse model.

49 mouse model of metastatic breast cancer, the polyoma middle T antigen (PyMT) transgenic mouse.

50 mary tumor virus long-terminal region-driven polyoma middle T antigen breast cancer model.

51 rring carcinomas of the mammary (MMTV-driven polyoma middle T antigen model, PyVmT) and prostate (TRA

52 roducing basal cells on activation of either polyoma middle T antigen or ErbB2 signaling.

53 antigen, were found to uniformly express the polyoma middle T antigen protein as well as 2',3'-cyclic

54 ast, elevated levels of SnoN cooperated with polyoma middle T antigen to accelerate the formation of

55 were crossed with transgenic mice expressing Polyoma middle T antigen under the control of the mouse

56 Mice expressing Polyoma middle T antigen under the mouse mammary tumor v

57 Virgin females carrying the Polyoma middle T antigen uniformly developed multiple, b

58 cancer, MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen), with Cav-1 (-/-)-null mice.

59 urine mammary tumor virus promoter linked to polyoma middle T antigen, a transgene that leads to rapi

60 CEINGE cl3 cells, immortalized with polyoma middle T antigen, were found to uniformly expres

61 om transgenic mice expressing Neu, H-Ras, or polyoma middle T antigen.

62 y tumor progression in mice that express the Polyoma middle T antigen.

63 rived vector) carrying the gene encoding the polyoma middle T antigen.

64 We tested these findings in vivo in the Polyoma middle T mammary tumor model in which p21CIP1 wa

65 Here, we show in the Polyoma Middle T mammary tumor model that N-cadherin (Cd

66 spontaneous breast cancer development in the polyoma middle T model.

67 In the current study, we have analyzed, in polyoma middle T oncogene (PyMT)-derived mammary tumors,

68 y epithelium during tumor development in the polyoma middle T oncogene (PyVT) mouse mammary tumor mod

69 With the help of the polyoma middle T oncogene driven breast cancer mouse mod

70 the overexpression of myc, ras, her2/neu, or polyoma middle T oncogenes.

71 of breast cancer caused by expression of the polyoma middle T oncoprotein (PyMT) in the mammary epith

72 were protected from tumors initiated by the polyoma middle T oncoprotein (PyMT), which activates Ras

73 In tumors from mice expressing the polyoma middle T oncoprotein (PyVT) in the mammary gland

74 tricted peptide, MT389-397, derived from the polyoma middle T oncoprotein.

75 rast, PTP1B deficiency has no effect on MMTV-polyoma middle T tumorigenesis.

76 e oncogenic transgenes MYC and Kras(D12), or polyoma middle T, and introduced into the systemic circu

77 Previously, mouse mammary tumor virus-driven polyoma middle T-antigen (MMTV-PyV MT) transgenic mice c

78 In the polyoma middle T-antigen (PyMT) transgenic mouse model o

79 development in the mouse mammary tumor virus-polyoma middle T-antigen model.

80 d crossed with the Mouse Mammary Tumor Virus-Polyoma Middle T-Antigen mouse.

81 etion of CX3CL1 in HER2/neu mice, but not in polyoma middle T-antigen oncomice.

82 The progression of polyoma middle T-antigen oncoprotein-induced mammary car

83 ur progression by using mammary tumour virus-polyoma middle T-antigen transgenic (PyMT) mice as a mod

84 Polyoma middle T-induced mammary carcinomas lacking the

85 imental model of human hemangiomas, in which polyoma middle T-transformed brain endothelial (bEnd) ce

86 bEND.3 cells are polyoma middle T-transformed mouse brain endothelial cel

87 Expression of thrombospondin-1 (TS1) in polyoma middle-sized T (tumor)-transformed mouse brain e

88 difier loci (Apmt1 and Apmt2) accelerate the polyoma Middle-T (PyVT)-induced mammary tumor.

89 enerated wild-type mouse mammary tumor virus/polyoma middle-T (WT/PyMT) and AIB3(+/-)/PyMT mice.

90 ed with mice expressing a dominant oncogene (polyoma middle-T antigen driven by the MMTV promoter, Py

91 mammary carcinogenesis using an orthotopic, polyoma middle-T antigen-driven model in Foxp3(DTR) knoc

92 ta complexed with the phosphoserine motif in polyoma middle-T was determined to 2.6 A resolution.

93 u to adenocarcinoma in widely used multistep polyoma-middle T-antigen transgenic mice.

94 One allograft was lost because of polyoma nephritis.

95 The fate of the genome of the polyoma (Py) tumor virus following integration in the ch

96 lograft dysfunction and failure, the risk of polyoma recurrence in a subsequent transplant is unknown

97 Polyoma small T antigen (PyST), an early gene product of

98 Enhancement of PP2A Abeta/Akt interaction by polyoma small T antigen increased turnover of Akt Ser-47

99 The oncoprotein polyoma small T interacts with PP2A to regulate survival

100 Interestingly, the polyoma small T-antigen (PyST), which shares with MTA bo

101 In addition, CD94/NKG2A(+) polyoma-specific CD8 T cells have a markedly enhanced ca

102 o Ag stimulation compared with CD94/NKG2A(-) polyoma-specific CD8 T cells.

103 We identified several novel polyoma-specific CD8(+) T cell epitopes in C57BL/6 mice,

104 These findings indicate that polyoma-specific CD8(+) T cells are armed with, but rest

105 results in deletion of Vbeta6 TCR-expressing polyoma-specific CD8+ CTL, which appear to be critical e

106 a cloning attempt, we discovered that while polyoma T antigen-positive Chinese hamster ovary cells (

107 ffectors in eliminating polyoma-infected and polyoma-transformed cells in vivo.

108 e syngeneic polyoma virus-infected cells and polyoma tumor cells.

109 tramer+CD8+ T cells efficiently infiltrate a polyoma tumor challenge to virus-immune mice.

110 hich appear to be critical effectors against polyoma tumorigenesis.

111 cytomegalovirus disease or infection, no BK/polyoma viral nephropathy, and no posttransplant prolife

112 Identification of risk factors for BK polyoma virus (BKPyV) without confounding by donor facto

113 This virus, termed cynomolgus polyoma virus (CPV), is antigenically and genomically re

114 e in control of viral pathogens including JC polyoma virus (JCV) infection.

115 hat some cases may be associated with the JC polyoma virus (JCV), which is also known to be latent in

116 er, which is associated with the Merkel cell polyoma virus (MCPyV).

117 Merkel cell polyoma virus (MCV) has been implicated in a majority of

118 Murine polyoma virus (MPyV) is a small DNA virus that induces t

119 Polyoma virus (PV) can cause interstitial nephritis and

120 Polyoma virus (Py) and simian virus 40 (SV40) travel fro

121 Polyoma virus (Py) differs from other small DNA tumor vi

122 In this study polyoma virus (Py) is used as a tool to better define th

123 Using mouse polyoma virus (PyV) as a model of low-level persistent v

124 cells transferred to SCID mice responded to polyoma virus (PyV) infection with T cell-independent (T

125 Using the mouse polyoma virus (PyV) persistent infection model, we recen

126 ighly susceptible to tumors induced by mouse polyoma virus (PyV), but CD8-deficient mice are resistan

127 Using mouse polyoma virus (PyV), we asked whether CD4(+) T cell help

128 Using mouse polyoma virus (PyV), we found that MHC class Ia-deficien

129 nation inhibition antibodies to the human JC polyoma virus and from 369 Amerinds from 13 tribes for h

130 he frequencies of precursor CTL specific for polyoma virus and MT(389-397) peptide were similar, indi

131 on procedure has been devised and applied to polyoma virus based on this rationale.

132 Reactivation of BK polyoma virus can result in destructive viral allograft

133 Importantly, CD94/NKG2A(+) anti-polyoma virus CD8 T cells appear to be essential for Ag-

134 racting (p53-TAg) or noninteracting (p53 and polyoma virus coat protein) pairs of proteins, treatment

135 two other alternative reading frames of the polyoma virus early region.

136 TL to recognize cells infected with a mutant polyoma virus encoding a MT truncated just proximal to t

137 The polyoma virus enhancer (PyE) is capable of conferring in

138 otein-2, CCAAT/enhancer-binding protein, and polyoma virus enhancer-3.

139 on, a mouse model was developed using murine polyoma virus expressing a defined CD4(+) T-cell epitope

140 Patients who had polyoma virus inclusions in renal allograft biopsies wer

141 as a therapeutic option in the management of polyoma virus induced graft failure.

142 The median time of diagnosis of polyoma virus infection after transplantation was 9.5 mo

143 In summary, persistent polyoma virus infection both quantitatively and qualitat

144 Polyoma virus infection causes acute interstitial nephri

145 Asymptomatic polyoma virus infection documented by urine cytology or

146 One animal had diarrhea and polyoma virus infection in the smooth muscle cells of th

147 Although polyoma virus infection is being increasingly recognized

148 Polyoma virus infection is characterized by lymphocytic

149 Previous graft loss secondary to polyoma virus infection is not a contraindication to ret

150 the B cells (CD20) in renal allografts with polyoma virus infection of 21% (range, 5-40%) compared w

151 The lymphocytic infiltrates of six cases of polyoma virus infection were compared with six cases of

152 pression predisposes cynomolgus monkeys to a polyoma virus infection with clinical consequences quite

153 Late in polyoma virus infection, early-strand mRNA levels are do

154 ograft survival was seen in patients who had polyoma virus infection.

155 c T cells in allografts is characteristic of polyoma virus infection.

156 ersible graft failure is more prevalent with polyoma virus infection.

157 and enumerate MT389-397-specific CTL during polyoma virus infection.

158 There were 10 cases of polyoma virus infections in renal transplant recipients.

159 54 to evaluate a rise in creatinine revealed polyoma virus interstitial nephritis.

160 The BK polyoma virus is a leading cause of chronic post kidney

161 Polyoma virus is a potent oncogenic pathogen when inocul

162 The natural mouse pathogen polyoma virus is highly oncogenic in H-2k mice carrying

163 Importantly, infection with a polyoma virus lacking MT389-397 and mutated in an MT236-

164 identified as a binding partner of the mouse polyoma virus large T antigen and later shown to possess

165 on into the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyV-mT) transgenic model.

166 mors in the mouse mammary tumor virus (MMTV)-polyoma virus middle T (PyVT) genetic model is delayed b

167 gene knockout and mouse mammary tumor virus-polyoma virus middle T antigen (MMTV-PyMT)-induced breas

168 growth factor receptors and proteins such as polyoma virus middle T antigen (MT).

169 titors in in vitro binding experiments using polyoma virus middle T antigen (MT).

170 itive cells (differentiated astrocytes) with polyoma virus middle T antigen (MTA).

171 (TK-/-) were crossed to mice expressing the polyoma virus middle T antigen (pMT) under the control o

172 Viruses encoding mouse polyoma virus middle T antigen (PyMT) induced tumors, wh

173 V-A-based RCAS vectors encoding either mouse polyoma virus middle T antigen (PyMT) or c-Myc to elasta

174 ed with the mouse mammary tumor virus (MMTV)-Polyoma virus middle T antigen (PyMT) or MMTV-c-Neu tran

175 (MMTV) promoter-driven Ptn expressed in MMTV-polyoma virus middle T antigen (PyMT)-Ptn mouse breast c

176 ssion using transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary g

177 erived from transgenic mice that express the polyoma virus middle T antigen (PyV-MT) in the mammary g

178 Polyoma virus middle T antigen (PyVmT) is a powerful vir

179 e G11 PLAP transgene was introduced into the polyoma virus middle T antigen mammary tumor model.

180 nse, we engineered mouse mammary tumor virus-polyoma virus middle T antigen mice with endothelial cel

181 ery of avian retroviruses encoding the mouse polyoma virus middle T antigen to elastase-tv-a transgen

182 after the somatic introduction of the mouse polyoma virus middle T antigen to mice with liver-specif

183 c PET and diffusion-weighted (DW)-MRI in the polyoma virus middle T antigen transgenic mouse model of

184 kt levels in total mouse mammary tumor virus-polyoma virus middle T antigen tumor lysates, suggesting

185 Transgenic expression of the polyoma virus middle T antigen, under control of the mou

186 which activates the erythropoietin receptor; polyoma virus middle T antigen, which resembles an activ

187 in transgenic mice expressing the oncogene, polyoma virus middle T antigen.

188 limits mammary tumor initiation in the MMTV-polyoma virus middle T genetic model.

189 background of the mouse mammary tumor virus/polyoma virus middle T oncogene (MMTV-PyMT) mammary canc

190 metastases [mouse mammary tumor virus-driven polyoma virus middle T oncogene (MMTV-PyVT)].

191 were either crossed with mice expressing the polyoma virus middle T oncogene specifically in the mamm

192 mammary tumors due to the expression of the polyoma virus middle T oncogene.

193 nase signaling is the principle mechanism of polyoma virus middle T oncoprotein activation of c-fos e

194 oic acid inhibits transformation of cells by polyoma virus middle T oncoprotein.

195 of Src family kinases to membrane-associated polyoma virus middle T-antigen (PyMT) can result in the

196 l, we crossed MT1-MMP-deficient mice to MMTV-polyoma virus middle T-antigen (PyMT) mice.

197 We have isolated spontaneous mutants of polyoma virus middle T-antigen (PyMT) that do not activa

198 nd3, isolated from mice transformed with the Polyoma virus middle T-antigen is available commercially

199 Although polyoma virus middle T-driven tumors showed altered prim

200 of the late-appearing mammary tumors of MMTV-polyoma virus middle T;Nedd9(-/-) mice are characterized

201 hways that are influenced by IRS-1 using the polyoma virus middle-T (PyV-MT) transgenic mouse model o

202 The clinical course of patients with polyoma virus nephritis (PVN) is not well understood, pa

203 (n=7), T-cell-mediated rejection (n=4), and polyoma virus nephropathy (n=1).

204 ade in an attempt to reduce the incidence of polyoma virus nephropathy (PVAN).

205 Polyoma virus nephropathy after transplantation is belie

206 in a subset of renal allograft kidneys with polyoma virus nephropathy.

207 ivity and 57 days for patients who developed polyoma virus nephropathy.

208 me viremic and three patients (1%) developed polyoma virus nephropathy.

209 This effect did not occur with wild-type polyoma virus or RBCs expressing HEL alone.

210 This highly focused CTL response to polyoma virus provides a valuable animal model to invest

211 The polyoma virus region expressed early in the lytic cycle

212 Leflunomide inhibits Polyoma virus replication in vitro and closely monitored

213 Transformation of cells in culture by polyoma virus requires integration of signals downstream

214 DNA extracted from affected kidneys detected polyoma virus sequences using primers for a highly conse

215 The simian polyoma virus SV40 has been detected in specific human t

216 lations with no known exposure to the simian polyoma virus SV40, also were tested for antibodies to t

217 e a manifestation of the activity of a human polyoma virus termed "JC." Among a total of 1,835 person

218 JC virus (JCV) is a polyoma virus that commonly infects humans.

219 g stimulated by the middle T-antigen (MT) of polyoma virus to address this question.

220 Polyoma virus tubulo-interstitial nephritis-associated g

221 xic effector function in mice susceptible to polyoma virus tumorigenesis.

222 Polyoma virus type BK (BKV) nephritis has emerged as an

223 In the present study, a hitherto unknown polyoma virus was detected in 12 of 57 cynomolgus monkey

224 e formation of long-term humoral immunity to polyoma virus was intrinsic to B cells and was independe

225 Infection with a mutant polyoma virus whose MT is truncated just before the MT38

226 Polyoma virus, a highly oncogenic natural mouse DNA viru

227 acute and persistent phases of infection by polyoma virus, a mouse pathogen that is capable of poten

228 In mice infected by polyoma virus, a natural mouse pathogen that establishes

229 g infection and preventing tumors induced by polyoma virus, a natural murine papovavirus.

230 l CD8(+) T cells in mice acutely infected by polyoma virus, a persistent mouse pathogen, specifically

231 lation for long-term control of infection by polyoma virus, a persistent mouse pathogen.

232 control infection with the B-cell-dependent polyoma virus, because plasma cells were markedly absent

233 antigen (PyST), an early gene product of the polyoma virus, has been shown to cause cell death in a n

234 ific CD8(+) T cells following infection with polyoma virus, influenza virus, and Listeria monocytogen

235 Recently, a newly described polyoma virus, Merkel cell polyomavirus (MCPyV), was fou

236 approach is used to explain the structure of polyoma virus, Simian Virus 40 and L-A virus capsids, wh

237 are highly susceptible to tumor induction by polyoma virus, whereas C57BR/cdj (BR) mice are highly re

238 Because the course of polyoma virus-associated nephropathy (PVAN) has not been

239 d case of successful retransplantation after polyoma virus-induced renal allograft loss.

240 L/6 mice, a mouse strain highly resistant to polyoma virus-induced tumors.

241 neonates having opposite susceptibilities to polyoma virus-induced tumors.

242 IA-1: median, 7%; range, 2-15%) were seen in polyoma virus-infected allografts compared with 24% (ran

243 ) H-2k mice that specifically lyse syngeneic polyoma virus-infected cells and polyoma tumor cells.

244 Polyoma virus-infected MyD88 knockout mice generated str

245 characterize the lymphocytic infiltrates in polyoma virus-infected renal allografts.

246 Persistent anemia, polyoma virus-like nephritis (n = 2), and urinary calciu

247 In comparison to a case-matched polyoma virus-negative control group, the PVN patients w

248 During the persistent phase of infection, polyoma virus-specific CD8 T cells that express CD94/NKG

249 ion is associated with Ag-specific recall of polyoma virus-specific CD8 T cells.

250 ) T-cell help for generating and maintaining polyoma virus-specific CD8(+) T cells.

251 CD4(+) T-cell help for the H-2(b)-restricted polyoma virus-specific CD8(+) T-cell response during acu

252 ly identified the immunodominant epitope for polyoma virus-specific CTL as the Dk-associated peptide

253 ly identified the immunodominant epitope for polyoma virus-specific CTL in tumor-resistant H-2k mice

254 d in an MT236-244 Dk anchor position induced polyoma virus-specific CTL recognizing neither MT389-397

255 l responses in mice persistently infected by polyoma virus.

256 ding sites were found on middle T antigen of polyoma virus.

257 ex vivo cytolytic activity and clearance of polyoma virus.

258 y conserved region of the large T antigen of polyoma virus.

259 nation inhibition antibodies to the human BK polyoma virus.

260 and usually fatal CNS infection caused by JC polyoma virus.

261 bition antibody titers against the JC and BK polyoma viruses (JCV and BKV, respectively) are signific

262 Capsids of papilloma and polyoma viruses (papovavirus family) are composed of 72

263 and origin-binding domains of papilloma and polyoma viruses evolved from a common ancestral protein

264 Although papilloma and polyoma viruses have differences in capsid size (approxi

265 ain significant antibody titers to the human polyoma viruses JC and BK but do not appear to contain e

266 The calcium bridge between the pentamers of polyoma viruses maintains capsid metastability.

267 rstanding the replication cycle of oncogenic polyoma viruses.

268 The crystal structure of polyoma VP1 with a sialic acid-containing oligosaccharid